-The Business Standard Patient safety & quality our guidance now, says Sawhney Trouble-hit Ranbaxy Laboratories has introduced a whistle-blower policy within the company to encourage transparency and address concerns internally, so that bigger problems could be averted. In his first interaction with the media (the first part of which was published on Sunday) since the drug maker pleaded guilty of making fraudulent statements to the US Food and Drugs Administration (FDA) under its...
More »SEARCH RESULT
Total Matching Records found : 828
USFDA scrutiny: Will pharma majors like Ranbaxy, Wockhardt be affected in long-term? -G Seetharaman
-The Economic Times japanese companies do not mind erring on the side of caution. They are known to think longer and harder than their counterparts in other countries about big decisions, especially when it comes to entering a new market or acquiring a foreign company. But japan's third biggest drugmaker Daiichi Sankyo would now wish it had spent more time doing due diligence on Ranbaxy Labs, in which it bought a...
More »In the Name of the Greater Good-Gopalkrishna Gandhi
-The Telegraph A village awaits doomsday By Jaideep Hardikar, Penguin, Rs 299 Why is the year, 2011, important? It is important for some states like West Bengal and Tamil Nadu, for it marked a change of government. But it is important, nationally, for the reason that 2011 was a census year. The data for Census 2011 has come, recently, into the public domain - which shows that our farmer population is shrinking....
More »Ranbaxy's dark chapter-Bhupesh Bhandari
-The Business Standard Why have Indian authorities woken up to the Ranbaxy case only now? The matter had been simmering for several years The Ranbaxy affair is one of the darkest chapters of India's business history. The company has admitted it fudged data so that it could launch its products in the United States. It has now paid $500 million as a penalty to settle the case. It is worse than Ramalinga...
More »Arvind Panagariya, a professor of Indian economics at Columbia University interviewed by Ullekh NP
-The Economic Times Arvind Panagariya, a professor of Indian economics at Columbia University, hits out at Nobel laureate and Harvard University professor Amartya Sen over his call to confront MPs with the "number of deaths" a delayed Food Security Bill can cause. The former chief economist at the Asian Development Bank counters Sen's argument that it is high social spending that has contributed to the economic growth of Asian economies such...
More »
